Supplementary table 1 from β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation
Year: 2023
Type: supplementary-materials
Abstract: The primary antibodies used were: β-Actin (Cell Signaling, #5125s), β-arrestin-2 Antibody (SantaCruz Biotechnology, sc-13140), Akt Antibody (Cell Signaling, # 9272), phospho-Akt (pT308) (epitomics, #2214-1), phospho-Akt (pS473) (epitomics, #2118-1), Cyclin A (Cell Signaling, # 4656s), Cyclin D1 (Abcam, ab 134175), CXCR7 Antibody (Proteintech, 20423-1-AP, and customized Antibody from Abmart, GeneTech), EGFR Antibody (Cell Signaling, #2646), phospho-EGFR (pY1110) (Abcam, ab68470, ab47370), phospho-EGFR (pY1068) (Epitomics, 1138-1), Lamin A/C (epitomics, 2966-1), phospho-p44/42 MAPK (pERK1/2) (cell signaling, #9106s), p44/42 MAPK (cell signaling, #9102), Src Family (Tyr416) Antibody (Cell Signaling, #2108), phospho-Src Family (pY416) Antibody (Cell Signaling, #2101), ɑ-Tubulin Antibody (Cell Signaling, #2144). Blots were probed with a 1:10,000 dilution of an anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibody (Cell Signaling).
Authors: Georgios Kallifatidis, Daniel Munoz, Rajendra Kumar Singh, Nicole Salazar, James J. Hoy, Bal L. Lokeshwar
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362612561